TScan Therapeutics (TCRX) Price to Sales (2021 - 2026)

TScan Therapeutics (TCRX) has reported Price to Sales for 6 consecutive years, with 121.17 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales rose 98.14% year-over-year to 121.17 in Q2 2026; TTM through Jun 2026 was 17.91, a 33.73% decrease from a year earlier, with the FY2025 full-year figure at 12.57, down 89.6% from the prior year.
• Price to Sales was 121.17 for Q2 2026 at TScan Therapeutics, down from 133.62 in the prior quarter.
• Over five years, Price to Sales peaked at 1330.94 in Q1 2024 and troughed at 7.48 in Q1 2023.
• A 5-year average of 245.7 and a median of 61.8 in 2023 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales soared 17697.55% in 2024 and tumbled 95.06% in 2025, its largest moves.
• Over 5 years, Price to Sales stood at 12.04 in 2022, then soared by 340.37% to 53.04 in 2023, then surged by 865.29% to 511.96 in 2024, then tumbled by 90.12% to 50.56 in 2025, then jumped by 139.67% to 121.17 in 2026.
• The last three Price to Sales figures came in at 121.17 (Q2 2026), 133.62 (Q1 2026), and 50.56 (Q4 2025), per Business Quant data.